Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Alzheimer’s Drug Discovery Foundation
New Alzheimer’s & Dementia Paper Highlights SpeechDx’s Role in Advancing AI-Driven Tools for Earlier Alzheimer’s Detection and Risk Assessment
June 22, 2026
Alzheimer’s Drug Discovery Foundation Begins Search for New Chief Science Officer as Co-Founder Dr. Howard Fillit Transitions to Emeritus Role
June 18, 2026
Clinical Trials on Alzheimer’s Disease Conference and Alzheimer’s Drug Discovery Foundation Partner to Advance Emerging Biotech Innovation at CTAD 2026
June 16, 2026
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
Goodes Prize Recipient Dr. Jeff Cummings’ 2026 Alzheimer’s Drug Pipeline Report Signals New Era of Biology-Driven Approaches
May 5, 2026
ADDF Launches New Phase of $150 Million Diagnostics Accelerator Initiative to Power Next Generation of Alzheimer’s Precision Medicine Worldwide
March 17, 2026
Alzheimer’s Drug Discovery Foundation Appoints Isobel Coleman as Chief Executive Officer to Lead Next Era of Alzheimer’s Breakthroughs
March 11, 2026
ADDF Bolsters Leadership Amid Transformative Moment in Alzheimer’s Research, Naming Gavin Cook and David Dolby to its Board and Appointing Jane McIntosh as Interim CEO
December 17, 2025
New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer’s Pathobiology
December 5, 2025
Readout of Phase 3 Semaglutide Trials Marks Critical Moment in Alzheimer’s Research and Suggests Potential for Combination Therapies
November 25, 2025
1
2
Next Page
→